2,869
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 12:32, 15 September 2023
, 15 September 2023→Studies
| Line 85: | Line 85: | ||
* oral admission at 9 AM | * oral admission at 9 AM | ||
| | | | ||
* 10 men | * 10 healthy men | ||
* 40-60 years | * 40-60 years | ||
| | | | ||
* | * admission was safe and well-tolerated | ||
|- | |- | ||
|Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women <ref>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550608/</ref> | |||
| | | | ||
* randomized, placebo-controlled, double-blind | |||
* 10-week | |||
* 250 mg/day | |||
| | | | ||
* 25 postmenopausal women with prediabetes | |||
* overweight or obese (BMI 25.3 - 39.1) | |||
* 56 - 66 years | |||
* 12 placebo, 13 NMN group | |||
| | | | ||
* increase in skeletal muscle insulin signaling, insulin sensitivity, and muscle remodeling | |||
* improvement in muscle insulin sensitivity is clinically relevant and is similar to the improvement observed after ~10% weight loss | |||
|- | |- | ||
| | | | ||